2 Mar 2020 08:18
Directorate change
Oxford, UK; 2 March 2020:Â Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the British Clinical AI technology company, today announces that Lorimer Headley, Chief Financial Officer and a Director of the Company, has left the business and the Board with immediate effect.
The Company expects to appoint an Interim Chief Financial Officer shortly and shall commence a search for a permanent replacement.
The Company's ongoing process to appoint a Non-executive Chair and additional independent Non-executive Directors is progressing and the Company expects to make further announcements in due course.
Commenting on the announcement, Professor Sir Bruce Keogh, Interim Chair of Sensyne Health, said:
"On behalf of the Board, I would like to thank Lorrie for his significant contribution to Sensyne over the past four years."
Â
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer | |
 Peel Hunt LLP (Nominated Adviser and Joint Broker) |  + 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Oliver Jackson | |
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma | |
Euan Brown | |
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Mary-Jane Elliott | |
Sukaina Virji | |
Melissa Gardiner | |
sensynehealth@consilium-comms.com |
Â
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com www.sensynehealth.com.
Â
Â